Hepatitis B vaccination: A completed schedule enough to control HBV lifelong?. Milan, Italy, 17-18 November 2011.

Vaccine

Volumn 31, Issue 4, 2013, Pages 584-590

  FitzSimons, David ^a   Hendrickx, Greet ^b   Vorsters, Alex ^b   Van Damme, Pierre ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Booster; Hepatitis B; Long term protection; Prevention; Vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; VIRUS DNA;

B LYMPHOCYTE; CELLULAR IMMUNITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEPATITIS B; HEREDITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; ITALY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT DURATION; VACCINATION;

ADULT; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; INFANT, NEWBORN; VACCINATION;

EID: 84871932530     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.101     Document Type: Conference Paper

References (48)

1. FitzSimons D., Francois G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005, 23(July 14 (32)):4158-4166.
2. World Health Organization Hepatitis B vaccines. WHO position paper. Wkly Epidemiol Rec 2004, 79(July 9 (28)):255-263.
3. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54(December 23 (RR-16)):1-31.
4. VHPB. Hepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes. Viral Hepatitis 2004 20; Available from: [accessed on 03.2.12]. http://www.vhpb.org/.
5. Leuridan E., Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011, 53(July 1 (1)):68-75.
6. Bialek S.R., Bower W.A., Novak R., Helgenberger L., Auerbach S.B., Williams I.T., et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008, 27(October (10)):881-885.
7. Poovorawan Y., Hutagalung Y., Chongsrisawat V., Thaemboonlers A., Lefevre I. Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age. Vaccine 2008, 26(March 17 (12)):1535-1540.
8. McMahon B.J., Dentinger C.M., Bruden D., Zanis C., Peters H., Hurlburt D., et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009, 200(November 1 (9)):1390-1396.
9. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Srinivasa K., Hutagalung Y., Bock H.L., et al. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 2009, 200(July 1 (1)):33-38.
10. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Bock H.L., Leyssen M., Jacquet J.M. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010, 28(January 8 (3)):730-736.
11. Zanetti A.R., Romano L., Giambi C., Pavan A., Carnelli V., Baitelli G., et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010, 10(November (11)):755-761.
12. Jan C.F., Huang K.C., Chien Y.C., Greydanus D.E., Davies H.D., Chiu T.Y., et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010, 51(May (5)):1547-1554.
13. Zhu C.L., Liu P., Chen T., Ni Z., Lu L.L., Huang F., et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 2011, 29(October 13 (44)):7835-7841.
14. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Leroux-Roels G., Crasta P.D., Hardt K. Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers. Hum Vaccin Immunother 2012, 8(July (7)):896-904.
15. CDC-Advisory Committee on Immunization Practices (ACIP). Available from: [accessed on 16.7.2012]. http://www.cdc.gov/vaccines/recs/acip/default.htm.
16. Salleras L., Dominguez A., Bruguera M., Cardenosa N., Batalla J., Carmona G., et al. Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and young people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the schools of Catalonia (Spain). Vaccine 2005, 23(March 18 (17-18)):2181-2184.
17. Chien Y.C., Jan C.F., Kuo H.S., Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006, 28:126-135.
18. Chongsrisawat V., Yoocharoen P., Theamboonlers A., Tharmaphornpilas P., Warinsathien P., Sinlaparatsamee S., et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006, 11(October (10)):1496-1502.
19. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Leroux-Roels G., Kuriyakose S., Leyssen M., et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011, 18(May (5)):369-375.
20. National Notifiable Disease Surveillance Sytem-CDC. Available from: [accessed on 04.9.2012]. http://www.cdc.gov/osels/ph_surveillance/nndss/nndsshis.htm.
21. Spada E., Tosti M.E., Zuccaro O., Stroffolini T., Mele A. Evaluation of the compliance with the protocol for preventing perinatal hepatitis B infection in Italy. J Infect 2011, 62(February (2)):165-171.
22. Viviani S., Carrieri P., Bah E., Hall A.J., Kirk G.D., Mendy M., et al. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(November (11)):3216-3223.
23. National Institute for Public Health and the Environment. Hepatitis B vaccination program. Available from: [accessed on 04.9.12]. http://www.rivm.nl/Onderwerpen/Ziekten_Aandoeningen/H/Hepatitis_B/Hepatitis_B_in_het_Rijksvaccinatieprogramma.
24. World Health Organization. Hepatitis B position paper preparation. Grading of scientific evidence (duration). Available from: [accessed on 03.02.12]. http://www.who.int/immunization/hepb_grad_duration.pdf.
25. World Health Organization Hepatitis B vaccines. WHO Position paper. Wkly Epidemiol Rec 2009, 84(October 1 (40)):405-419.
26. Bauer T., Hepatitis Jilg W. B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24(January 30 (5)):572-577.
27. Hollinger F.B. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989, 87(September 4 (3A)):36S-40S.
28. Inskip H.M., Hall A.J., Chotard J., Loik F., Whittle H. Hepatitis B vaccine in the Gambian Expanded Programme on Immunization: factors influencing antibody response. Int J Epidemiol 1991, 20(September (3)):764-769.
29. Gesemann M., Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995, 13(April (5)):443-447.
30. Zanetti A.R., Mariano A., Romano L., D'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005, 366(October 15-21 (9494)):1379-1384.
31. Roznovsky L., Orsagova I., Kloudova A., Tvrdik J., Kabieszova L., Lochman I., et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection 2010, 38(October (5)):395-400.
32. van der Sande M.A., Waight P., Mendy M., Rayco-Solon P., Hutt P., Fulford T., et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006, 193(June 1 (11)):1528-1535.
33. Ryckman K.K., Fielding K., Hill A.V., Mendy M., Rayco-Solon P., Sirugo G., et al. Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis. PLoS ONE 2010, 5(8):e12273.
34. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980, 303(October 9 (15)):833-841.
35. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986, 315(July 24 (4)):209-214.
36. Francis D.P., Hadler S.C., Thompson S.E., Maynard J.E., Ostrow D.G., Altman N., et al. The prevention of hepatitis B with vaccine, Report of the centers for disease control multi-center efficacy trial among homosexual men. Ann Intern Med 1982, 97(September (3)):362-366.
37. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007, 120(August (2)):e373-e381.
38. van der Sande M.A., Waight P.A., Mendy M., Zaman S., Kaye S., Sam O., et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2007, 2(1):e753.
39. Lu C.Y., Ni Y.H., Chiang B.L., Chen P.J., Chang M.H., Chang L.Y., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008, 197(May 15 (10)):1419-1426.
40. Chinchai T., Chirathaworn C., Praianantathavorn K., Theamboonlers A., Hutagalung Y., Bock P.H., et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol 2009, 22(April (2)):125-130.
41. Steiner M., Ramakrishnan G., Gartner B., Van Der Meeren O., Jacquet J.M., Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010, 10:9.
42. Kao J.T., Wang J.H., Hung C.H., Yen Y.H., Hung S.F., Hu T.H., et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009, 27(March 13 (12)):1858-1862.
43. Chang M.H. Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants. Antivir Ther 2010, 15(3 Pt B):463-469.
44. Nan X., Shi S., Yu C., Zhuang H. Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection. Hepatol Res 2010, 40(December (12)):1176-1187.
45. Jilg W., Van Damme P. Editorial. Viral Hepat 2004, 13(1).
46. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005, 142(March 1 (5)):333-341.
47. Tosti ME. Presentation on VHPB website: Breakthrough HBV infections in vaccinated people: a ten-year surveillance study in Italy. 2011 Available from: [accessed on 04.09.12]. http://www.vhpb.org/files/html/Meetings_and_publications/Presentations/MILS53.pdf.
48. Teo C.G., Locarnini S.A. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther 2010, 15(3 Pt B):445-449.